|Bid||4.3900 x 2900|
|Ask||4.3700 x 4000|
|Day's range||4.2200 - 4.6400|
|52-week range||3.9900 - 18.1600|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||11.50|
Looking for investment opportunities in the healthcare sector, and particularly in the biotechnology industry, can be overwhelming if you're not intimately familiar with the space. Here are three companies that operate surprisingly diverse operations -- either through drug pipeline variety, customer diversification, or differentiated product verticals -- offering a safety net, as well as prospects for growth, to their shareholders as a result. Led by its mission "to help people access, understand, and benefit from the human genome," 23andMe Holding (NASDAQ: ME) has quietly identified over 40 therapeutic programs from its treasure trove of genetic data.
You've probably noticed that stock market volatility has picked up recently. While nobody enjoys watching the value of their investments go down, periods of volatility like this one can create opportunities to get into long-term winners at a discount. Here are two, in particular, that have 10X growth potential (or possibly much more) that are at the top of my watch list as we head toward 2022.
In this segment of Backstage Pass, recorded on Nov. 12, Fool.com contributors Toby Bordelon, Jon Quast, and Rachel Warren each name an IPO stock that long-term investors might want to put on their radar for 2022. With so many IPOs, sometimes, it's hard to keep up.